Bristol Myers to Build Most Powerful AI Factory in Life Sciences with NVIDIA
BMY sits 43% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb is expanding its AI infrastructure with NVIDIA's latest DGX Vera Rubin systems, creating what it calls the most powerful single-owned NVIDIA setup in life sciences. The move builds on a three-year collaboration and aims to accelerate drug discovery across oncology, immunology, and other areas. The new architecture promises up to 10x better performance per megawatt, enabling larger AI workloads without a proportional energy increase. This signals a serious commitment to AI-driven R&D, with early results already showing time savings in target identification and molecule design. The investment could sharpen BMS's competitive edge in a sector where AI is becoming a key differentiator.
At the time of this announcement, BMY was trading at $60.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $124B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.